Comparative Pharmacology
Head-to-head clinical analysis: MEZLIN versus PFIZERPEN VK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MEZLIN versus PFIZERPEN VK.
MEZLIN vs PFIZERPEN VK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mezlocillin is a ureidopenicillin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically inhibiting transpeptidase activity, leading to cell lysis.
Penicillin V binds to penicillin-binding proteins (PBPs) located on the bacterial cell wall, inhibiting transpeptidase activity and disrupting peptidoglycan cross-linking, leading to cell lysis via autolytic enzymes.
3-4 g intravenously every 4-6 hours; maximum 24 g/day.
250-500 mg orally every 6 hours for mild to moderate infections; 500 mg orally every 6 hours for severe infections. For group A streptococcal pharyngitis: 250 mg orally 3 times daily or 500 mg twice daily for 10 days.
None Documented
None Documented
Terminal elimination half-life is 0.7-1.2 hours in healthy adults; prolonged to 2-5 hours in renal impairment (CrCl <20 mL/min) and up to 10-20 hours in ESRD.
Terminal half-life: 30–60 minutes in adults with normal renal function; prolonged in renal impairment (up to 4–10 hours in anuria).
Renal (70-80% unchanged via glomerular filtration and tubular secretion); biliary (approximately 2-3%); fecal (minor).
Renal: ~60-80% unchanged via tubular secretion; biliary/fecal: minor (hepatic elimination of metabolites).
Category C
Category C
Antibiotic (Penicillin)
Antibiotic (Penicillin)